-
Takeda-Led Group Begins Manufacturing COVID-19 Plasma Treatment, Says Confident Of Efficacy
Tuesday, October 13, 2020 - 1:32am | 364Read More...A group led by Takeda Pharmaceutical Company Limited (NYSE: TAK) has begun manufacturing a blood plasma treatment for COVID-19, even as late-stage human testing remains pending, the company’s CEO Christophe Weber told Reuters Monday. What Happened: The CoVIg Plasma Alliance, composed of...
